FDA Warning Letter

An FDA Warning Letter is a public correspondence from FDA notifying a regulated entity of significant violations of the Federal Food, Drug, and Cosmetic Act, demanding prompt corrective action. Warning Letters are published on FDA's website. They typically follow an inspection that produced a Form 483, an inadequate response, or otherwise serious observed conditions. The recipient has 15 business days to respond. FDA may take further action (consent decree, injunction, recall, criminal referral) if the response is inadequate or the violations are not corrected.

How an FDA Warning Letter works

The Warning Letter is drafted by the FDA District Office and reviewed by the relevant Center (CDER, CDRH, CBER, CFSAN). It identifies each violation by reference to specific statute and regulation, summarizes the underlying facts (usually drawn from inspection observations), demands corrective action, requests a written response within 15 business days, and notes the potential consequences if the response is inadequate or the violations recur. The letter is publicly posted to FDA's website on issuance.

The 15-business-day response is the recipient's first formal opportunity to address each cited violation with specificity. A strong response includes documented corrective action (not promises), root-cause analysis, implementation timelines, and management commitments. FDA reviews the response and determines whether to close the matter, request follow-up information, or escalate. Closeout produces a separate FDA letter; escalation can produce a referral to the Office of Chief Counsel, a referral to DOJ for civil injunction proceedings, or a criminal referral under the Park doctrine.

When an FDA Warning Letter applies

Warning Letters issue to drug manufacturers, medical device manufacturers, food facilities, dietary supplement manufacturers, biologics manufacturers, and increasingly to 503B outsourcing facilities and 503A compounding pharmacies that operate outside the 503A framework. The most active recent enforcement focus has been compounded GLP-1 and peptide preparations, where FDA issued over 135 Warning Letters across the 2024 to 2026 enforcement wave. International facilities can receive Warning Letters with parallel import alert action.

The recipient's exposure under an FDA Warning Letter

The most immediate exposure is reputational: the Warning Letter is public and discoverable in every customer relationship, lender covenant, M&A diligence review, and parallel state regulatory inquiry. The downstream enforcement risk includes consent decree (a court-ordered compliance framework that can shut down operations), injunction, recall, import alert, criminal referral under the Park doctrine, and parallel False Claims Act exposure where the cited violations supported government-program claims. The defense framework focuses on the 15-day response, root-cause documentation, parallel state board posture, and pre-emptive resolution where consent-decree negotiation is preferable to injunction litigation.

Related terms

• FDA Form 483 The inspectional observations document that often precedes a Warning Letter.
• 503A and 503B The compounding pathways most active in current FDA Warning Letter enforcement.
• USP 797 and 800 The compounding practice standards whose violations frequently support Warning Letters.
• OIG self-disclosure The parallel pre-enforcement mechanism for healthcare program matters distinct from FDA enforcement.

See also

• Practice area
  FDA Warning Letter Response

  The full Warning Letter defense framework, including the 15-day response strategy and escalation defense.

• Practice area
  Compounding Pharmacy Defense

  The compounding defense pillar spanning 503A, 503B, USP, and FDA enforcement coordination.